Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): Quality of life (QoL) and pain palliation results from the global phase III study.

被引：0
|
作者：
Moinpour, C
Wu, J
Donaldson, G
Liepa, A
Melemed, A
Oshaughnessy, J
Rappold, E
Albain, K
机构：
[1] SW Oncol Grp, Ctr Stat, Seattle, WA USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] Univ Utah, Salt Lake City, UT 84112 USA
[4] US Oncol Res Inc, Dallas, TX USA
[5] Loyola Univ, Med Ctr, Maywood, IL 60153 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
621
引用
收藏
页码：32S / 32S
页数：1
相关论文
共 50 条
  • [11] Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
    Hans-Joachim Lück
    Andreas Du Bois
    Sibylle Loibl
    Iris Schrader
    Jens Huober
    Volker Heilmann
    Matthias Beckmann
    Ann Stähler
    Christian Jackisch
    Michael Hubalek
    Barbara Richter
    Elmar Stickeler
    Holger Eidtmann
    Christoph Thomssen
    Michael Untch
    Kerstin Wollschläger
    Tibor Schuster
    Gunter von Minckwitz
    Breast Cancer Research and Treatment, 2013, 139 : 779 - 787
  • [12] Preliminary results of a randomized phase II study of paclitaxel and bevacizumab ± gemcitabine as first-line treatment for metastatic breast cancer
    Hoelzer, K. L.
    Brufsky, A.
    Hainsworth, J.
    Beck, J. T.
    Whorf, R.
    Keaton, M.
    Kroener, J.
    Krill-Jackson, E.
    Hu, S.
    Bromund, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [13] Paclitaxel (P) maintenance following first line chemotherapy with anthracyclines plus paclitaxel in metastatic breast cancer (MBC): preliminary results from the MANTA 1 study.
    Conte, PF
    ANNALS OF ONCOLOGY, 2000, 11 : 23 - 23
  • [14] Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
    Di Leo, Angelo
    Gomez, Henry L.
    Aziz, Zeba
    Zvirbule, Zanete
    Bines, Jose
    Arbushites, Michael C.
    Guerrera, Stephanie F.
    Koehler, Maria
    Oliva, Cristina
    Stein, Steven H.
    Williams, Lisa S.
    Dering, Judy
    Finn, Richard S.
    Press, Michael F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (34) : 5544 - 5552
  • [15] First-line treatment with lapatinib plus paclitaxel versus paclitaxel alone for patients with HER2+metastatic breast cancer (MBC): Quality-of-life (QOL) analysis using repeated measures and pattern mixture models
    Sherrill, B.
    Wu, Y.
    Amonkar, M.
    Arbushites, M.
    DiLeo, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [16] A Randomized Phase II Study of Paclitaxel and Bevacizumab With and Without Gemcitabine as First-Line Treatment for Metastatic Breast Cancer
    Brufsky, Adam
    Hoelzer, Karen
    Beck, Thaddeus
    Whorf, Robert
    Keaton, Mark
    Nadella, Padma
    Krill-Jackson, Elisa
    Kroener, Joan
    Middleman, Edward
    Frontiera, Michael
    Paul, Devchand
    Panella, Timothy
    Bromund, Jane
    Zhao, Luping
    Orlando, Mauro
    Tai, Fritz
    Marciniak, Martin D.
    Obasaju, Coleman
    Hainsworth, John
    CLINICAL BREAST CANCER, 2011, 11 (04) : 211 - 220
  • [17] Combination versus sequential paclitaxel plus gemcitabine as first-line chemotherapy for women with metastatic breast cancer: a prospective randomized phase II study
    Shao, Bin
    Song, Guohong
    Li, Huiping
    Di, Lijun
    Jiang, Hanfang
    Liang, Xu
    Yan, Ying
    Zhang, Ruyan
    Ran, Ran
    Wang, Jing
    Liu, Xiaoran
    You, Miaoning
    JOURNAL OF BUON, 2018, 23 (06): : 1583 - 1590
  • [18] Phase III study of gemcitabine (G) plus paclitaxel (T) versus T in patients with metastatic breast cancer (MBC) - Post-study chemotherapy (PSC) trend analysis
    Llombart, A.
    Nag, S.
    Calderillo-Ruiz, G.
    Rolski, J.
    Pluzanska, A.
    Simms, L.
    Looks, K.
    Gill, J.
    Melemed, A.
    O'Shaughnessy, J.
    EJC SUPPLEMENTS, 2008, 6 (07): : 217 - 217
  • [19] nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
    Yardley, D. A.
    Coleman, R.
    Conte, P.
    Cortes, J.
    Brufsky, A.
    Shtivelband, M.
    Young, R.
    Bengala, C.
    Ali, H.
    Eakel, J.
    Schneeweiss, A.
    de la Cruz-Merino, L.
    Wilks, S.
    O'Shaughnessy, J.
    Gluck, S.
    Li, H.
    Miller, J.
    Barton, D.
    Harbeck, N.
    ANNALS OF ONCOLOGY, 2018, 29 (08) : 1763 - 1770
  • [20] Biweekly gemcitabine–paclitaxel, gemcitabine–carboplatin, or gemcitabine–cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial
    Binghe Xu
    Zefei Jiang
    Sung-Bae Kim
    Shiying Yu
    Jifeng Feng
    Artur Malzyner
    Auro del Giglio
    Hyun C. Chung
    Li Jun Shen
    Daniel Lee Kay Pen
    Breast Cancer, 2011, 18 : 203 - 212
12345